FGFR3::TACC3 fusion-positive gliomas demonstrate a relatively favorable prognosis, with better outcomes than FGFR3::TACC3-negative glioblastomas, although still poorer than those of IDH-mutant gliomas [[6], [7], [8]]. This evidence concerns the gene FGFR3 and central nervous system cancer.